UPDATED: Lilly antibody drug fails in COVID-19 study for hospitalized patients
| Associated Press and IBJ Staff
The discontinuation of the study, along with the release of third-quarter earnings that fell short of analysts’ expectations, caused Lilly shares to fall 3.5% in premarket trading Tuesday.